subcutaneous
BMS and Halozyme announce positive results for subcutaneous Opdivo in cancer patients
Anika Sharma
Following the discontinuation of an auto-injected version of Opdivo (nivolumab), Bristol Myers Squibb (BMS) has achieved success with a more ...
